[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363147-105":59,"doc-detail-363147-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","investigating-the-secreted-proteome-of-primary-and-metastatic-human-brain-tumour-explants-maintained-on-a-miniaturised-perfusion-device","Investigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device","","Non-invasive approaches for brain tumour detection and diagnosis are constrained by the lack of clinically validated circulating biomarkers. This study uses a miniaturised tissue perfusion model to keep human brain tumour tissue ex vivo while profiling tissue-derived secreted proteins for biomarker potential. Fifty-five samples from 11 tumour types were perfused for 168 h and analysed using reversed-phase capillary LC-MS/MS, with ELISA quantification of ECM1 and cathepsin D. Proteomic profiling identified 90 proteins and revealed higher ECM1 in high-grade glioma effluent, supporting further validation in patient serum or cerebrospinal fluid.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/investigating-the-secreted-proteome-of-primary-and-metastatic-human-brain-tumour-explants-maintained-on-a-miniaturised-perfusion-device/363147/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/investigating-the-secreted-proteome-of-primary-and-metastatic-human-brain-tumour-explants-maintained-on-a-miniaturised-perfusion-device/363147.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of this study?","Question",{"text":113,"@type":114},"To identify proteins secreted by primary and metastatic human brain tumours that could serve as circulating biomarkers for non-invasive detection and diagnosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the tumour tissues maintained during the experiments?",{"text":118,"@type":114},"Tumour samples were micro-dissected and kept ex vivo on a continuous-flow microfluidic perfusion device for 168 hours with nutrient supply and waste removal.",{"name":120,"@type":111,"acceptedAnswer":121},"Which proteins were specifically quantified, and what did ELISA show?",{"text":122,"@type":114},"ECM1 and cathepsin D were quantified by ELISA; ECM1 levels were significantly higher in high-grade glioma effluent than in low-grade glioma, while cathepsin D did not differ significantly between tumour types.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363147,1790536187,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nInvestigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device  \nSamuel G. Perkins 1,2, Sabrina F. Samuel 1, Richard J. Digby 1,3, Heiko Wurdak 1, John Greenman 4, * and Ryan K. Mathew 1,2, *  \nReceived: 12 February 2026  \nRevised: 16 March 2026  \nAccepted: 24 March 2026  \nPublished: 25 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Medicine, University of Leeds, Leeds LS2 9JT, UK; [samuel.perkins2@nhs.net](samuel.perkins2@nhs.net) (S.G.P.); [s.f.samuel@leeds.ac.uk](s.f.samuel@leeds.ac.uk) (S.F.S.); [richard.digby1@nhs.net](richard.digby1@nhs.net) (R.J.D.); [h.wurdak@leeds.ac.uk](h.wurdak@leeds.ac.uk) (H.W.)  \n2 Department of Neurosurgery, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK  \n3 Department of Cellular Pathology, St. James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK  \n4 Centre for Biomedicine, Hull York Medical School, University of Hull, York YO10 5DD, UK  \n* [Correspondence: j.greenman@hull.ac.uk](Correspondence: j.greenman@hull.ac.uk) (J.G.); [r.k.mathew@leeds.ac.uk](r.k.mathew@leeds.ac.uk) (R.K.M.)  \nSimple Summary  \nBrain tumours are relatively rare and particularly difficult to diagnose because simple diagnostic tests such as blood tests are not yet in routine clinical practice. Typically, expensive and lengthy brain scans are required. In this study, we kept human brain tumour samples alive outside the body using a microfluidic device to supply the tissue continuously with nutrients whilst simultaneously removing waste products. This allowed us to directly study the proteins released by the tumours, with the goal of identifying those that could form the basis of a diagnostic blood test. We detected many proteins that have previously been reported as potential tumour markers, as well as several that have not been studied in this context before. Some of the proteins identified were linked to tumour aggressiveness. The combination of tissue-based microfluidics and proteomic analysis have provided a novel way of determining blood-based markers for early and accurate brain tumour detection and diagnosis.  \nAbstract  \nBackground: Non-invasive approaches to brain tumour detection and diagnosis are limited by the absence of clinically validated circulating biomarkers. This study utilised a miniaturised tissue perfusion model to maintain human brain tumour tissue ex vivo with the aim of identifying tissue-derived proteins with potential biomarker utility. Methods:  \n55 tumour samples from 11 different brain tumours (glioblastoma n = 4, low-grade glioman = 4, brain metastases n = 3) were micro-dissected and maintained ex vivo on a continuousflow perfusion device for 168 h. Proteomic analysis of tumour effluent was performed by reversed-phase capillary liquid chromatography-mass spectrometry. Two candidate proteins—extracellular matrix protein 1 (ECM1) and cathepsin D—were quantified using ELISA. Results: All tumour subtypes retained tissue viability over 168 h of perfusion. Proteomic profiling identified 90 tissue-derived proteins in the tumour effluent. Many proteins corresponded to previously described cancer biomarkers such as glial fibrillary acidic protein (GFAP) while others, including Serpin A12 and collapsin response mediator protein-2 (CRMP2), had not yet been described in a brain tumour context. ELISA confirmed significantly higher ECM1 levels in high-grade glioma effluent compared with low-grade glioma (p = 0.0407), whereas cathepsin D levels did not differ significantly  \nbetween tumour types. Conclusions: The ex vivo perfusion model effectively preserved primary and metastatic human brain tumour tissue and enabled direct characterisation of tumour-secreted proteins. The proteins id","cbCaisGE8g22MXPB","https://ap.wps.com/l/cbCaisGE8g22MXPB","pdf",2044104,17,"English","# Simple Summary\n# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To identify proteins secreted by primary and metastatic human brain tumours that could serve as circulating biomarkers for non-invasive detection and diagnosis.\"},{\"question\":\"How were the tumour tissues maintained during the experiments?\",\"answer\":\"Tumour samples were micro-dissected and kept ex vivo on a continuous-flow microfluidic perfusion device for 168 hours with nutrient supply and waste removal.\"},{\"question\":\"Which proteins were specifically quantified, and what did ELISA show?\",\"answer\":\"ECM1 and cathepsin D were quantified by ELISA; ECM1 levels were significantly higher in high-grade glioma effluent than in low-grade glioma, while cathepsin D did not differ significantly between tumour types.\"}]","Investigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device | PDF",1790150178,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66a6d4c999fb827b528627004dc31f3a.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/536de3620656f8134e34842b406976c3.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f520ccf497e80d03ebd440db2f5b914.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86d035a87c3981d3bd36e294573e01dc.webp",980,1385]